The vast majority of animal data derived blockers (CCBs) with regard to their effects on surrogate end-points of renal disease progression . from models of either remnant kidney or diabetes demonstrate that dihydropyridine (nifedipine-like) cal-These end-points include the rate of decline in glomerular filtration rate (GFR) as well as changes in albucium-channel blockers (DHPCCBs) effectively reduce arterial pressure but do not significantly affect pro-minuria and proteinuria. Moreover, in all animal models of diabetic nephropathy as well as the remnant teinuria nor prevent development of glomerular scarring. Conversely, the non-DHPCCBs such as diltiazem kidney model, DHPCCBs have universally failed to prevent glomerular scarring as well as reduce increases and verapamil blunt both the rise in proteinuria as well as mesangial matrix expansion and subsequent in proteinuria [16, 17, [20] [21] [22] [23] . These changes relate to a failure of DHPCCBs to effect key mechanisms that glomerular scarring in diabetes. Additionally, the nonDHPCCBs markedly attenuate development of glom-are altered during the natural history of these disease processes. erular scarring in the remnant kidney model. The primary reasons for these differences between sub-
Introduction
variable cellular distribution of a given calcium channel. Clearly there is more than a single calcium channel Over the past decade there have been significant differthat these drugs inhibit. ences noted between the subclasses of calcium-channel CCBs as a class have quite divergent morphological and to a lesser extent haemodynamic effects on the Correspondence and offprint requests to: George L. Bakris MD, kidney ( Table 1) . This is largely due to the fact that Department of Preventive Medicine, Rush-Presbyterian-St Luke's [ 17, 19 ] Partially abolished [ 21] * (see a+b above) **Decreased only if blood pressure markedly reduced. P GC , intraglomerular pressure. *Responses to ACE inhibitors are similar in remnant kidney animal model. Note, however, that renal autoregulatory mechanisms are not affected by ACE inhibitors. +High sodium intake, Á200 mEq/day will blunt reductions in glomerular permeability.
calcium channels into low-voltage-activated (T-type) strated that antihypertensive agents that fail to reduce proteinuria also fail to significantly alter the natural and high-voltage-activated types: L-type, dihydropyridine-sensitive, and N-type, v-conotoxin GVIA-history of renal disease progression [9, 12, 16, 23, 30, 31] .
One of the primary reasons that albuminuria may sensitive. Experimental use of various toxins has led to the further subclassification of high-voltage-correlate with glomerular injury in animal models of diabetes relates to its degree of glycation. The level of activated channels to P-type, Q-type, and R-type [24] . It is the L-type calcium channel that is abundant in blood sugar will determine the amount of glycated albumin in the circulation [32, 33] . Glycated albumin the cardiovascular system and that, within the last few years, has been isolated and cloned. Its subunits have has been shown to increase mesangial matrix protein expression and production leading to the morpholobeen identified and its amino-acid composition determined [25 ] . The L-type calcium channels comprise five gical changes associated with diabetic nephropathy [34] [35] [36] . Thus, increased membrane permeability at subunits termed a 1 , a 2 , b, c and d. The a 1 subunit appears to be responsible for channel opening and the glomerulus will increase the likelihood that glycated albumin will be exposed to mesangial cells and subvoltage dependency and it contains receptors for calcium channel antagonists. These geographically dis-sequently stimulate cellular activity.
A recent randomized, parallel group study with a tinct receptors correspond to each of the three different chemical classes of antagonists, exemplified by diltia-2-year follow-up in patients with NIDDM associated nephropathy, supports the concept that nonzem, nifedipine and verapamil. Diltiazem appears to have an inhibitory effect on mitochondrial sodium-DHPCCBs reduce membrane permeability, especially to large molecules while DHPCCBs do not manifest calcium exchange that is unique among calciumchannel antagonists [26 ] . Additionally, calcium chan-this benefit [37] . These differences in permeability effects by CCBs could not be explained by differences nels have an unequal distribution as well as differential binding throughout the neural and cardiovascular sys-in blood pressure between groups. This failure of DHPCCBs to improve glomerular permeabililty, howtems [27] [28] [29] . Hence, a particular subclass of CCBs such as the DHPCCBs will have their own channel to ever, may be explained, in part, by a lack of responsinhibit and subsequently yield different biological iveness to L-channel inhibition on the efferent arteriole effects when compared to other channel blockers.
[38]. This would consequently result in an inability to lower intraglomerular pressure in spite of blood pressure reduction, hence, indirectly maintaining increased
Differences in glomerular permeability
permeability of the membrane. Lastly, it should be noted that high sodium intake blunts this reduction in permeability associated with non-DHPCCBs [39 ]. Three recent meta-analyses review studies on renal ACE inhibitors as well as non-DHPCCBs have been disease progression in both animal models of diabetes shown to attenuate the increase in matrix protein as well as clinical studies of diabetic and non-diabetic synthesis induced by glycated albumin [2, 18, 40] . While, renal disease [8, 9, 23] . These meta-analyses found that the mechanism of this effect is unknown, it may help non-DHPCCBs and ACE inhibitors had the greatest to explain why non-DHPCCBs may slow the glomerefficacy for reducing proteinuria. Moreover, it was ular scarring process observed in diabetes. Such effects noted that a strong correlation exists between reduchave not been described with any DHPCCB [7-9, tions in proteinuria and an attenuated development of 16, 23] . glomerulosclerosis [8, 9, 23] . All animal studies reviewed This failure of DHPCCBs to alter glomerular perfor these meta-analyses demonstrate that a reduction meability is unclear. It may relate, however, to the in arterial pressure without a blunted rise in proteinuria differential distribution of calcium channels on the result in a failure to blunt the progression to glomerular glomerular membrane. One could postulate that if scarring [9, 23] . Moreover, all biopsy studies as well as studies that evaluate changes in GFR have demon-L-channels were either sparsely disbursed or quiescent on the glomerular membrane no effect on permeabililty kidney as well as effects on vascular action of angiotensin II [41, 42] . Non-DHPCCBs and other antihyperwould be observed by these DHPCCBs. Conversely, if calcium channels associated with diltiazem and verapa-tensive agents have either minimal or no significant effects on renal autoregulation [19 ] . Table 2 summarmil activity were more prevalent this would lead to decreases in permeability associated with non-izes the effects of the different antihypertensive drug classes on renal autoregulation. DHPCCBS. Thus, since increased leakiness to glycated albumin clearly increases glomerular injury, independThree separate studies using 24-h blood pressure monitoring in a rat remnant kidney model demonstrate ent of arterial pressure load, non-DHPCCBs may provide unique and independent protection to the that blood pressure reduction with ACE inhibitors does not significantly affect the renal autoregulatory kidney, apart from arterial pressure reduction.
process [17, 19, 21] . Blood pressure reduction with nonDHPCCBs, while partially interfering with renal auto-
Renal autoregulation
regulation, still allows some preservation of this inherent protective biological process. Conversely, treatment with DHPCCBs totally obliterates autoregulation and Another possible explanation for the differences allows for linear association of pressure to be transmitbetween dihydropyridine and non-DHPCCBs is their action on renal autoregulation. Renal autoregulation ted through the glomerular capillary bed [17, 19] . [14, 52, 53] 
nephropathy with one in patients with IDDM associfunction with a DHPCCB blood pressure reduction would have to be reduced to a systolic level of ated nephropathy. Moreover, there are no long-term studies, to date, that examine the effects of CCBs in <110 mmHg to equal the same level of renal protection associated with a systolic pressure of 140 mmHg patients with IDDM associated nephropathy.
The completed studies, however, demonstrate a clear observed with an ACE inhibitor. A similar association may be demonstrated when a comparison between benefit when non-dihydropyridine CCBs are used over conventional therapy, i.e. b blocker on both progresdihydropyridine and non-DHPCCBs is examined ( Figure 1) . Thus, in addition to a lack of effect on sion of nephropathy and reduction in proteinuria [5, 6 ] .
Specifically, one study of 52 patients with NIDDMglomerular permeability, dihydropyridine may also abolish the kidneys normal ability to protect itself associated nephropathy and hypertension, randomized to either an ACE inhibitor ( lisinopril ), non-dihyagainst the pressure head by obliterating autoregulatory processes.
dropyridine CCBs (verapamil or diltiazem SR), or a beta blocker (atenolol ) and followed for 6 years, demonstrated that the greatest mean rate of Clinical studies decline in creatinine clearance was in the atenolol group (−3.4 ml/min/year/1.73 m2 ) with no differences between the lisinopril (−1.1 ml/min/year/1.73 m2 ) and When one considers the effects of any blood-pressurelowering agent on preservation of renal function they non-dihydropyridine CCB (−1.5 ml/min/year/1.73 m2 ) groups [5] . Moreover, while the degree of bloodmust consider the following variables: (1 ) the natural history of the disease being studied, (2 ) the stage of pressure reduction was similar in all groups, proteinuria was reduced to a similar extent only in the disease which is present at the time of recruitment into the study, (3 ) the level of blood pressure reduction as lisinopril and the non-dihydropyridine CCB groups.
These observations were further exemplified in a 5-year well as the duration of control in each patient evaluated in a given study, ( 4) and lastly, the sodium intake of randomized study among African-American patients with NIDDM nephropathy. In this study, verapamil the patient especially if the variable being studied is albuminuria or proteinuria. An extensive discussion as was associated with a 62% slower progression of renal disease when compared to a beta blocker, given similar to why these factors are critically important in a given study design and their impact on data interpretation reductions in arterial pressure [6 ] .
Conversely, studies on NIDDM-associated renal disis beyond the scope of this paper. The reader, however, is referred to several reviews of these topics [43] [44] [45] [46] [47] .
ease progression with dihydropyridine agents have, with one exception, thus far failed to show any signiIn the natural history of diabetic nephropathy, especially that from insulin dependent diabetes mellitus ficant reduction in albuminuria or slowed progression in nephropathy [54] . The equivalent results on albu-( IDDM), it takes between 3 and 8 years for microalbuminuria to develop [44, 45] . Hypertension generally minuria reduction and GFR decline between amlodipine and cilazapril were not surprising, however, given develops in about 40% of IDDM patients and 25% of non-insulin-dependent diabetic (NIDDM ) patients the degree of renal disease present in these patients, that is, microalbuminuria with a GFR between 75 and [44, 45] . All diabetic patients with hypertension will ultimately develop end-stage renal disease requiring 90 ml/min. Moreover sodium intake, which has been shown to be a critical determinant of albuminuria dialysis [44, 45, 48] .
The average rate of decline in GFR in such reduction associated with ACE inhibitor as well as a non-DHPCCB use [39, 55, 56 ] , was neither controlled patients ranges from 1.5 to 2.5 ml/min/year in patents treated with ACE inhibitors or non-DHPCCBs to for nor measured. Additionally, Velussi et al. document a marked reduction in GFR with amlodipine relatively 10-12 ml/min/year in those whose arterial pressure is uncontrolled [5, 6, 49, 50] . This rate of decline in renal early in the course of the disease process. This observation is contrary to all other published studies that function primarily depends on the level to which blood pressure is reduced as well as the medications used to demonstrate 2-10% increase in inulin clearance with DHPCCBs [12,16]. achieve such a level. Thus it is clear for substantial differences in declines of renal function to be appreciSodium intake was also not measured in a separate study by Zucchelli et al. that documents similar effects ated between different treatment groups the duration of follow-up must be a minimum of 3 years. between a DHPCCB and an ACE inhibitor on renal survival at 2 years of follow-up [51]. However, this Unfortunately surrogate end-points of renal disease progression such as changes in proteinuria have been study further documents a greater than fivefold increase in the number of people starting dialysis in examined in thousands of patients for periods of up to 2 years. Thus, for the previously mentioned reasons, third-year follow-up who were randomized to nifedipine. Thus to date there is no meaningful data with we will only discuss studies that have 'long-term' follow-up, i.e. greater than or equal to a 3-year DHPCCBs by which anyone can assess their effect on renal disease progression. Conversely, two previously duration.
There are three completed [5,6,51] and three ongoing discussed long-term studies in patients with NIDDM-associated nephropathy demonstrate similar benefits carefully from among the CCB subclasses to optimize a given patients cardiorenal profile. between an ACE inhibitor and non-DHPCCB on renal disease progression.
Summary CCBs and cardiovascular disease
To date there is insufficient evidence to conclude that one particular CCB should be viewed as having the It is curious, with all the available data from clinical best overall profile on either the kidney or heart. trials on cardiovascular disease, that the DHPCCBs However, data is growing to support the concept of have failed to show any reduction in mortality from two specific subclasses of CCBs with regard to their ischaemic heart disease [57, 58] . Notable is the PRAISE effects on both cardiovascular and renal end-points. trial, which failed to show a reduction in cardiovascular Specifically, DHPCCBs generally do not reduce proevents among patients with ischaemic heart disease. teinuria nor markedly slow progression of renal disMoreover, in this trial of over a thousand people with ease. Moreover, their effects on diabetic renal disease severe heart failure, renal function significantly progression appear to be correlated solely with their worsened in 7.7% of patients randomized to the ability to lower blood pressure. Conversely non-DHPCCB, amlodipine, as compared to the 3.6% in DHPCCBs slow progression of advanced diabetic renal the placebo group, P=0.002 [58] . If the effect of disease to a degree similar to that observed with an amlodipine on tubular secretion of creatinine, how-ACE inhibitor. Moreover, their renal benefits do not ever, is similar to other dihydropyridine CCBs, this appear to be related solely to blood-pressure reduction worsening in renal function may be simply explained as seen with DHPCCBs. by a decreased creatinine secretion induced by the drug and not represent a true worsening of renal function [59 ] . Interestingly, this lack of benefit on ischaemic References heart disease events with DHPCCBs is in contrast to as compared to 37% who were taking ACE inhibitors since the major cause of death in diabetic patients is 13. Hatov C, Pavlova M, Demetrakov D, Veleukov H, Bakalov B.
The influence of nifedipine on renal function in patients with due to cardiovascular disease, one needs to select
